ISSN: 1301-2193 E-ISSN: 1308-9846
  • Turkish Journal of
    Endocrinology and Metabolism

Introduction

Now-a-days, as a result of change in lifestyles and eating habits, the chemistry of human body is changing. Junk foods, lack of exercise, and psychosocial stress are important among the various reasons leading to dreadful metabolic disorders. Metabolic syndrome (MetS) is one of them. MetS is a constellation of interrelated risk factors of metabolic origin - metabolic risk factors - that appear to promote the development of atherosclerotic cardiovascular disease (CVD) (1). It consists of atherogenic dyslipidemia, elevations of blood pressure (BP) and glucose, prothrombotic and proinflammatory states (2). The constellation of dyslipidemia [hypertriglyceridemia and low levels of high-density lipoprotein cholesterol (HDLc)], elevated BP, impaired glucose tolerance, and central obesity is now classified as MetS (3).

The definitions of MetS include those proposed by the World Health Organization, the European Group for the Study of Insulin Resistance, the US National Cholesterol Education Program (NCEP) and the International Diabetes Federation (IDF) (4,5,6,7).

Obesity and physical inactivity are the driving forces behind the syndrome while metabolic susceptibility is required for MetS to manifest (8) This includes adipose tissue disorders, genetic and racial factors, aging, and endocrine disorders (9). Two primary clinical outcomes of MetS are CVD and non-insulin-dependent diabetes mellitus, which both are leading causes of morbidity and mortality worldwide. In fact, all individual components of MetS are risk factors for CVD and MetS has been shown to be the most important factor responsible for myocardial infarction in the population younger than 45 years of age (10).

Insulin Resistance and Obesity

The most accepted hypothesis to describe the pathophysiology of the MetS is insulin resistance. Risk factors for the syndrome appear to be abdominal obesity and insulin resistance (11). Insulin resistance is contributed by free fatty acids (FFAs) which reduce insulin sensitivity in muscle by inhibiting insulin-mediated glucose uptake. Increased circulating glucose results in hyperinsulinemia. In the liver, FFAs increase the production of glucose, triglycerides and very low-density lipoproteins leading to reduced glycogen formation and increased lipid accumulation in triglycerides (TG) (12). Insulin resistance leads to increased lipolysis to produce more fatty acids, further inhibiting the antilipolytic effect of insulin, leading to lipolysis (13). Abnormal production of inflammatory cytokines from adipose tissue may affect insulin resistance (14). Obesity is related to control of BP and insulin resistance through oxidative stress (15,16). Ultimately, oxidative stress has been shown to correlate with dyslipidemia and abdominal fat in patients with MetS and thus might be considered as a linking factor between various components of MetS.

Paraoxonase

In the history, paraoxonases (PONs) dates back long as Aldridge in 1953, classified estearses depending upon their interaction with organophosphate (OP) compounds. According to this, “A” esterases are those hydrolyzing OPs and “B” esterases are those inhibited by OPs. PONs belong to group “A” while cholinesterases belong to group “B” (17,18). PON requires Ca++ for its stability and action which distinguishes it from other group “A” esterases which require Co++, Mn++, Mg++. They are widely distributed in the body including liver, kidney, small intestine, serum (19). PON enzymes were originally discovered as enzyme-hydrolyzing exogenous OP compound, such as insecticide paraoxon. PON is a family of three enzymes, PON1, PON2 and PON3, the gene which is located on chromosome 7q21.3-22.1 (20).

Paraoxonase 1

The enzyme was first noticed as PON1 which is exclusively associated with HDLs and is a genetically polymorphic enzyme. This is a HDL-associated enzyme which plays a vital role in the prevention of micro-vascular complications due to oxidative stress and various toxic chemicals (21). HDL oxidation is prevented by PON1-mediated hydrolysis of lipid peroxides and of cholesteryl linoleate hydroperoxides because peroxidase like activity of PON1 protects against oxidation (22). By far the most studied member of the family is serum PON1 (E.C 3.1.8.1), a 45 kDa protein, a calcium-dependent esterase/lactonase whose primary physiological role is to protect low-density lipoproteins (LDLs) from oxidative modifications (23). Recent investigations have suggested that the hydrolytic activity towards lactones (cyclic esters) is the native activity of PON1: Structure-activity studies show that lactones are PON1’s preferred substrate for hydrolysis (24). Certain studies have shown that molecules implicated in acute-phase inflammatory responses, cytokines and oxidized phospholipids reduce both PON1 expression and its PON activity (25). Diabetes mellitus which is a component of MetS is associated with an elevated level of oxidative stress, increased susceptibility to coronary heart disease, and reductions in PON1 concentration and PON activity (26). It is noted in obese diabetes patients that PON1 activities are reduced with elevated leptin and oxidative stress (27). Human PON1 is predominantly synthesized in the liver from where it is secreted into the blood and associated with HDL. The objective of the present study was to estimate PON1 arylesterase (ARE), lactonase activity (LACT) in patients with MetS and to compare PON1 activities in patients with MetS and controls.

Materials and Methods

The study has been undertaken with due approval from the Institutional Ethics Committee. A total of 80 subjects were included in the study. Sample size is calculated using 2-sided confidence interval 95% and power 80%. Using the mean and standard deviation form in our pilot study, necessary sample size comes out to be 33. Therefore, a total of 40 subjects were enrolled each as cases and controls. Cases have been selected randomly from patients visiting the hospital to avoid the selection bias. Cases were included as per the criteria put forth by the IDF. Age- and sex-matched controls were selected from the population attending the regular medical checkup in the hospital. IDF criteria is: Central obesity plus 2 or more of the following - fasting glucose ≥100 mg/dL or previously diagnosed type 2 diabetes, TG ≥150 mg/dL or specific treatment for this lipid abnormality, HDLc <40 mg/dL in males and <50 mg/dL in females or specific treatment for this lipid abnormality and systolic BP ≥130 mm Hg diastolic BP ≥85 mm Hg or treatment of previously diagnosed hypertension.

As per the Declaration of Helsinki, written informed consent were taken from all the participants. With all aseptic precautions, early morning fasting blood samples were collected by venipuncture from all patients. From control subjects, blood samples were collected through venipuncture at the time of their routine clinical visits. The samples were analyzed immediately after processing.

Serum PON1 ARE activity was measured spectrophotometrically at 270 nm with 3 mL buffer-substrate solution containing 20 mmol Tris-hydroxymethyl (HCI) buffer and 4 mmol phenylacetate as substrate at pH 8.0 and 5 μl serum. Serum PON1 LACT was measured spectrophotometrically at 270 nm with 2 mL buffer-substrate solution containing 50 mmol Tris-HCl buffer and 1 mmol dihydroxycoumarine as substrate at pH 8.0 and 10 μl serum. Normality of the distribution of the ARE and LACT was assessed by the Shapiro-Wilk test (28,29). Normality of the distribution of the ARE and LACT was assessed by the Shapiro-Wilk test. The two-sample t-test was applied for hypothesis testing. The results were expressed as mean ± standard deviation for all continuous variables. The statistical significance level was set at 0.05. There were no differences  between the two groups with regard to age and sex. Linear regression was used to examine the relationship between one dependent and one independent variable. After performing an analysis, the regression statistics can be used to predict the dependent variable when the independent variable is known. Regression goes beyond correlation by adding prediction capabilities. Therefore, we also used the linear regression for the analysis. The result of linear regression is given in terms of R2 which is a statistical measure of how close the data are to the fitted regression line. It is also known as the coefficient of determination. It indicates the proportion of the variance in the dependent variable that is predictable from the independent variable. In general, the higher the R2, the better the model fits your data. The results obtained were analyzed by using SPSS 20.0.

Results

Serum PON1 ARE activity was found to be reduced significantly in patients with MetS than in controls. Similarly, serum PON1 LACT was found to be reduced significantly in patients with MetS. The results show that the ARE and lactonase singly can correlate well with body mass index (BMI) and their combination even more so. The study parameters are shown in the Table 1.

Figure 1 and 2 show the distribution of the PON1 ARE and LACT respectively in cases and controls. Figure 3 and 4 show correlation of PON1 ARE and lactonase respectively with BMI.

Correlation coefficient (r) for HDL with PON1 ARE comes out to be 0.150 (p<0.001) while for PON1 LACT was 0.071 (p=0.014). This positive correlation of HDL with PON activities shows that PON activities are well associated with HDL. Linear regression analysis shows R2=0.246 indicating significant correlation between ARE and BMI (p<0.001). Similarly, serum LACT of PON1 also gets reduced with increased BMI. Its linear regression analysis showed R2=0.417 suggesting a significant correlation between lactonase and BMI (p<0.001). Both these show a significant negative correlation with BMI. Along with other parameters, the difference between patients and controls for fasting blood glucose and diastolic BP was also statistically significant. Correlation coefficient (r) for diastolic BP was 0.083 (p=0.036) with PON1 ARE and 0.079 (p=0.042) with PON1 LACT. Correlation coefficient (r) for fasting blood glucose was 0.134 (p=0.018) with PON1 ARE and 0.102 (p=0.029) with PON1 LACT.

Discussion

To the best of our knowledge, ours is the first study investigating the correlation of MetS with serum ARE and LACT in combination. Plasma PON1 activity was found to be altered, usually decreased in number of pathological conditions and diseases (30). In the present study, we found that there was a significant reduction in PON1 ARE and LACT in cases of MetS.

It appears that ARE and LACT of PON1 are new and independent markers for MetS. Some of the researchers have found a significant negative correlation between oxidative stress and PON1 levels (31). It can be hypothesized that oxidative damage to the lipoproteins especially to HDL leads to reduced PON1 activity as oxidative stress levels are high in MetS due to deranged glycemic control and hyperinsulinemia (32).

Biochemical findings of MetS have shown reduced HDLc. Decreased concentration of HDLc is correlated with reduced PON1 activities (33). Our results depict, though not very significant, a positive correlation of HDLc with ARE and lactonase.

Reduced PON1 activities are supposed to be a consequence of dysfunctional or modified HDLc which is responsible for reduced antioxidant capacity (34). As PON1 prevents oxidation of LDL and HDL, qualitative changes in lipoproteins coupled with reduced HDLc concentration leading to reduced PON1 activity, render them more susceptible to oxidative damage. There is a progressive decline in enzymatic capacity of PON1 with disease severity of MetS. Inactivation of PON1 (35) is likely to be the consequence of oxidative stress in, exceeding the antioxidant capacity of the enzyme. This can be the possible explanation of reduced PON1 activity.

The literature states that severity of MetS is directly proportional to oxidative stress which inactivates PON1 function (36). However, at the same time, the possibility that low PON1 function fails to provide an efficient protection against MetS-related oxidative damage can not be excluded.

PON1 is capable of protecting lipoproteins from lipid peroxidation by degrading specific oxidized cholesteryl esters and phospholipids, and antioxidant properties of HDL have been attributed, at least partially to PON1 (36). This may be the possible explanation for reduced PON1 activity found in MetS. Some researchers revealed that a low PON1 concentration is characteristic of MetS, independently of low HDLc concentration. It has also been proposed that these results invite to take into account not only HDL quantity but also HDL quality, which could be reflected, at least in part by PON1 concentration or activity (37). This is because PON1 is a HDL-associated enzyme. This supports the findings that PON1 correlates well with MetS.

The reductions in the activities of PON1 found in the present study and their relationship with HDL-cholesterol suggest that the decrease in these serum enzymes may participate in the pathogenesis of MetS.

The altered PON1 ARE and LACT in MetS could have two possible explanations. One is that serum PON1 activities may be lowered as a result of an altered synthesis or secretion of HDLc. The other one is the overproduction of circulating inhibitors like lipid peroxidation products and various free radicals. Free radicals are disproportionately formed in metabolic abnormalities, such as chronic hyperglycemia, (38) dyslipidemia (39) by oxidation and subsequent oxidative degradation of proteins. Insulin resistance seems to stimulate endothelial superoxide anion production via nicotinamide adenine dinucleotide phosphate hydrolase (40) and hence, can worsen the degree of oxidative stress. Taken together, these observations strongly suggest that the activation of oxidative-stress pathways is a key component of MetS.

From the present study, it is clear that reduction in PON1 activities in MetS are mainly due either to abnormalities with synthesis or secretion of HDLc or oxidative stress which is a consequence of excess production of free radicals. This study also iterates that it is the “quality” and not the quantity of HDLc which needs to be taken into account while studying the pathophysiology of MetS and PON1 effectively put forth the ‘quality’ of HDLc. It is also suggested from the present study that obesity is an important factor for enhanced oxidative stress and it is associated with lower antioxidant PON1 enzymatic activity. The combination of oxidative stress, obesity complication, dyslipidemia, deranged glycemic control and insulin resistance could contribute to the greater risk of MetS Therefore, our study recommends PON1 as a tool to assess the severity of MetS.

Ethics

Ethics Committee Approval: Approved by Institutional Ethical Committee, Informed Consent: Written informed consent was taken as per Helsinki declaration.

Peer-review: Externally peer-reviewed.

Authorship Contributions

Surgical and Medical Practices: Mukund Mogarekar, Mohit Rojekar, Concept: Mukund Mogarekar, Mohit Rojekar, Design: Mukund Mogarekar, Mohit Rojekar, Data Collection or Processing: Mohit Rojekar, Analysis or Interpretation: Mukund Mogarekar, Mohit Rojekar, Literature Search: Mohit Rojekar, Arati Adhe-Rojekar, Writing: Mohit Rojekar, Arati Adhe-Rojekar.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

References

1.    National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421.
2.    Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 2008;28:629-636.
3.    Alshehri AM. Metabolic syndrome and cardiovascular risk. J Family Community Med 2010;17:73-78.
4.    Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-553.
5.    Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999;16:442-443.
6.    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
7.    Alberti KG, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome--a new worldwide definition. Lancet 2005;366:1059-1062.
8.    Grundy SM. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab 2007;92:399-404.
9.    Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2003;163:427-436.
10.    Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G, Melchionda N. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999;107:450-455.
11.    Lemieux I, Pascot A, Couillard C, Lamarche B, Tchernof A, Alméras N, Bergeron J, Gaudet D, Tremblay G, Prud’homme D, Nadeau A, Després JP. Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 2000;102:179-184.
12.    Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-1428.
13.    Eckel RH, Yost TJ, Jensen DR. Alterations in lipoprotein lipase in insulin resistance. Int J Obes Relat Metab Disord 1995;19:16-21.
14.    Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796-1808.
15.    Pessler D, Rudich A, Bashan N. Oxidative stress impairs nuclear proteins binding to the insulin responsive element in the GLUT4 promoter. Diabetologia 2001;44:2156-2164.
16.    Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006;440:944-948.
17.    Aldridge WN. Serum esterases. I. Two types of esterase (A and B) hydrolysing p-nitrophenyl acetate, propionate and butyrate, and a method for their determination. Biochem J 1953;53:110-117.
18.    Aldridge WN. Serum esterases. II. An enzyme hydrolysing diethyl p-nitrophenyl phosphate (E600) and its identity with the A-esterase of mammalian sera. Biochem J 1953;53:117-124.
19.    Mackness B, Durrington PN, Mackness MI. Human serum paraoxonase. Gen Pharmacol 1998;31:329-336.
20.    Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996;33:498-507.
21.    Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993;104:129-135.
22.    Rosenblat M, Karry R, Aviram M. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes. Atherosclerosis 2006;187:74-81.
23.    Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001;21:473-480.
24.    Khersonsky O, Tawfik DS. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 2005;44:6371-682.
25.    Van Lenten BJ, Wagner AC, Navab M, Fogelman AM. Oxidized phospholipids induce changes in hepatic paraoxonase and ApoJ but not monocyte chemoattractant protein-1 via interleukin-6. J Biol Chem 2001;276:1923-1929.
26.    Mackness B, Durrington PN, Boulton AJ, Hine D, Mackness MI. Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controls. Eur J Clin Invest 2002;32:259-264.
27.    Be?towski J, Wójcicka G, Jamroz A. Leptin decreases plasma paraoxonase 1 (PON1) activity and induces oxidative stress: the possible novel mechanism for proatherogenic effect of chronic hyperleptinemia. Atherosclerosis 2003;170:21-29.
28.    Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983;35:1126-1138.
29.    Billecke S, Draganov D, Counsell R, Stetson P, Watson C, Hsu C, La Du BN. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos 2000;28:1335-1342.
30.    Vlachos GD, Bartzeliotou A, Schulpis KH, Partsinevelos GA, Lazaropoulou C, Papadima C, Papastamataki M, Antsaklis A, Papassotiriou I. Maternal-neonatal serum paraoxonase 1 activity in relation to the mode of delivery. Clinical Biochem 2006;39:923-928.
31.    Ferretti G, Bacchetti T, Moroni C, Savino S, Liuzzi A, Balzola F, Bicchiega V. Paraoxonase activity in high-density lipoproteins: a comparison between healthy and obese females. J Clin Endocrinol Metab 2005;90:1728-1733.
32.    Eren E, Abuhandan M, Solmaz A, Taşkın A. Serum paraoxonase/arylesterase activity and oxidative stress status in children with metabolic syndrome. J Clin Res Pediatr Endocrinol 2014;6:163-168.
33.    Dullaart RP, Kwakernaak AJ, Dallinga-Thie GM. The positive relationship of serum paraoxonase-1 activity with apolipoprotein E is abrogated in metabolic syndrome. Atherosclerosis 2013;230:6-11.
34.    Garin MC, Kalix B, Morabia A, James RW. Small, dense lipoprotein particles and reduced paraoxonase-1 in patients with the metabolic syndrome. J Clin Endocrinol Metab 2005;90:2264-2269.
35.    Sentí M, Tomás M, Fitó M, Weinbrenner T, Covas MI, Sala J, Masiá R, Marrugat J. Antioxidant paraoxonase 1 activity in the metabolic syndrome. J Clin Endocrinol Metab 2003;88:5422-5426.
36.    Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998;101:1581-1590.
37.    Martinelli N, Micaglio R, Consoli L, Guarini P, Grison E, Pizzolo F, Friso S, Trabetti E, Pignatti PF, Corrocher R, Olivieri O, Girelli D. Low levels of serum paraoxonase activities are characteristic of metabolic syndrome and may influence the metabolic-syndrome-related risk of coronary artery disease. Exp Diabetes Res 2012;2012:231502.
38.    Maritim AC, Sanders RA, Watkins JB Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol 2003;17:24-38.
39.    Le NA. Hyperlipidaemia and cardiovascular disease. Curr Opin Lipidol 2001;12:587-589.
40.    McCarty MF. Insulin’s stimulation of endothelial superoxide generation may reflect up-regulation of isoprenyl transferase activity that promotes rac translocation. Med Hypotheses 2002;58:472-475.